Seeking Alpha

Celgene Corporation (CELG)

  • Feb. 20, 2013, 8:45 AM
    Celgene (CELG +1.8%) agrees to buy back $600M in stock from an investment bank as part of its repurchase program. So far this year, the company has bought back $385M in shares and has $1.45B remaining in the scheme. Celgene has repurchased $5.05B of stock over the past four years.
    | 1 Comment
  • Feb. 11, 2013, 8:38 AM
    The FDA has granted a priority review to Celgene's (CELG +2.1%) Revlimid drug for patients with relapsed or refractory mantle cell lymphoma (MCL) after prior therapy. Revlimid, in combination with the steroid dexamethasone, has also won approval from China's State Food & Drug Administration for use in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. (PR)
    | Comment!
  • Feb. 8, 2013, 4:30 PM
    The FDA approves Celgene's (CELG) Pomalyst brand therapy for patients with multiple myeloma. The approval is based on response rate; as of yet, clinical benefit, such as improvement in survival or symptoms, has not been verified.
    | Comment!
  • Jan. 24, 2013, 2:23 PM
    Celgene (CELG -1%) slips after posting a lackluster Q4 report, with earnings matching analyst expectations while revenue falls just short of estimates. The company reaffirms its FY13 outlook with revenue just shy of expectations, expecting to earn between $5.50 to $5.60 a share with 11% sales growth on around $6B in sales. The Street is looking for an EPS of $5.64 on $6.1B in revenue.
  • Jan. 24, 2013, 7:33 AM
    Celgene (CELG): Q4 EPS of $1.32 in-line. Revenue of $1.42B (+14% Y/Y) misses by $0.03B. (PR)
    | Comment!
  • Jan. 24, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Jan. 23, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ABC, ALK, ARG, AVT, BAX, BMY, BPOP, CELG, CY, DOV, EQT, ESI, ETN, FCS, GWW, JNS, JVA, KCG, KEY, LMT, LUV, MKC, MMM, MWW, NMM, NOK, ORI, PCP, QSII, RTN, RYN, SWK, TZOO, UAL, UNP, XRX
    | Comment!
  • Jan. 23, 2013, 2:43 PM
    Threshold Pharmaceuticals (THLD +18%) soars after Celgene (CELG -0.7%) reported positive Phase III data for Abraxane, its prospective treatment for pancreatic cancer, but the data came in slightly below analysts' expectations. Stifel Nicolaus reiterated a Buy on THLD after the news, saying that its own treatment will be more competitive with CELG's product.
    | Comment!
  • Jan. 8, 2013, 8:25 AM
    Celgene (CELG +1.4% to $86.92) is the subject of lots of analyst buzz after the company gave a positive forecast yesterday. Jefferies raises its price target to $104 from $94 while Stifel Nicolaus ups its goal to $98 from $89, with both firms maintaining Buy ratings. RBC upgrades Celgene to Outperform from Sector Perform and ups its target to $100 from $90, while Piper Jaffray upgrades the biotech to Overweight from Neutral.
    | Comment!
  • Jan. 7, 2013, 2:32 PM
    Celgene Corp. (CELG +3.1%) updates guidance, saying it expects FY12 income to come in at the higher end of previous estimates and in-line results for 2013. Net product sales are expected to double between 2013 and 2017, reaching over $12B, with numerous milestones expected in 2013 for three "potential blockbuster" drugs. One of the drugs is its existing cancer drug Abraxane, which it hopes to have approved as a treatment for pancreatic cancer - which is among the hardest to treat - sometime this year.
    | Comment!
  • Dec. 11, 2012, 9:33 AM
    Celgene's (CELG +0.8%) pomalidomide, in combination with a low dose of the steroid dexamethasone, helped patients with multiple myeloma live a median 3.6 months without their disease worsening in a Phase III study. That's above the 1.8 months for the blood cancer patients taking just a high dose of the steroid. The FDA is due to decide whether to approve pomalidomide by Feb 10. Analysts reckon pomalidomide could generate sales of over $1B/year by 2017. (PR)
    | Comment!
  • Nov. 12, 2012, 9:10 AM
    Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
    Losers: CLVS -41%. STSI -20%. NBG -11%.
    | Comment!
  • Nov. 12, 2012, 8:44 AM
    In contrast to Clovis' share-price collapse, Celgene (CELG) is +8.6% after saying on Friday that its Abraxane treatment for advanced pancreatic cancer lengthened the survival of patients in a Phase III study. Pancreatic cancer could add up to $1B in sales of Abraxane, which is already approved to treat breast and lung tumors.
    | 1 Comment
  • Nov. 9, 2012, 5:38 PM
    Celgene (CELG) says Phase 3 studies of Abraxane, a treatment for advanced pancreatic cancer, met its primary endpoint of overall survival. Based on the results, the company plans to submit applications for registration in the U.S., Europe and other markets.
    | Comment!
  • Oct. 25, 2012, 10:40 AM
    Celgene (CELG +0.7%) says that abstracts reviewing results from a phase III metastatic melanoma study with Abraxane for the upcoming Society for Melanoma Research meeting have been published online in the organization’s official journal. Results from the study show that the drug demonstrates significant improvement in progression-free survival when compared to standard chemotherapy in advanced melanoma patients. (abstract)
    | Comment!
  • Oct. 25, 2012, 9:04 AM
    More on Celgene (CELG +1.8%) Q3: net profit +14% to $424.2M. Revlimid (blood-cancer) +18% to $970M, Vidaza (Blood cancer) +15% to $220M despite loss of patent protection in 2011. Raises FY EPS estimate to $4.85-$4.90 from increased July estimate of $4.80-$4.85 and vs consensus of $4.88; narrows revenue guidance to $5.45B-$5.55B vs consensus of $5.5B.
CELG vs. ETF Alternatives
Company Description
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States